PCSK9 inhibitor to stabilize artery plaques after heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a powerful cholesterol-lowering drug (PCSK9 inhibitor) helps stabilize plaque in heart arteries after a recent heart attack or unstable angina treated with a stent. It may lower the risk of future heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have had a recent heart attack or unstable angina that was treated with a stent.
- You have a second, partially blocked artery (in a native vessel, not a bypass graft) that can be safely examined with a special camera.
- You have not had a stroke in the last 6 months, never had a brain bleed, and do not have advanced heart failure.
- You have not taken a strong cholesterol-lowering injection (PCSK9 inhibitor) in the past 6 months.
- You are willing to return for follow-up visits and tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
This trial tests whether a single injection of a PCSK9 inhibitor (a cholesterol-lowering medicine) can improve heart health after a stent procedure. It is for people who have a certain amount of fat buildup in their treated artery.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This study looks at how well doctors can treat multiple blocked heart arteries using a specific drug-eluting stent, aiming to fully open them. It may help patients whose blockage pattern fits the study, but it does not include certain high-risk or special cases.
This trial uses advanced imaging (OCT) and single-cell analysis to study different types of plaque in people with coronary artery disease. It aims to understand how these plaque types differ at a cellular level, which could lead to better treatments.
This study tests whether starting a cholesterol-lowering drug called a PCSK9 inhibitor soon after a heart attack can help prevent future blockages. If you had a heart attack, received a stent, and have other arteries with minor blockages, this trial may be for you.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.